Download PDF
Thromb Haemost 1981; 46(03): 645-647
DOI: 10.1055/s-0038-1653438
Original Article
Schattauer GmbH Stuttgart

Stability of Prostacyclin in Human Plasma and Whole Blood: Studies on the Protective Effect of Albumin

M A Orchard
The Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, U. K
,
C Robinson
The Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, U. K
› Author Affiliations
Further Information

Publication History

Received 10 June 1981

Accepted 18 August 1981

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The biological half-life of prostacyclin in Krebs solution, human cell-free plasma or whole blood was measured by bracket assay on ADP-induced platelet aggregation. At 37°C, pH 7.4, plasma and blood reduced the rate of loss of antiaggregatory activity compared with Krebs solution. The protective effect of plasma was greater than that of whole blood. This effect could be partially mimicked by the addition of human or bovine serum albumin to the Krebs solution. The stabilisation afforded by human serum albumin was dependent on the fatty acid content of the albumin, although this was less important for bovine serum albumin.

Keywords

Prostacyclin half-life - Serum albumins - Platelet aggregation
 

  • References

  • 1 Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation. Lancet 1977; 1: 18-20
    PubMedGoogle Scholar
  • 2 Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin Ex and D2 on platelet aggregation in different species. Prostaglandins 1978; 16: 373-388
    CrossrefPubMedGoogle Scholar
  • 3 Cho MJ, Allen MA. Chemical stability of prostacyclin (PGI2) in aqueous solutions. Prostaglandins 1978; 15: 943-954
    CrossrefPubMedGoogle Scholar
  • 4 Pedersen KA, Stoffersen E, Dyerberg J. Stability of prostacyclin in plasma. Lancet 1979; 1: 1352
    PubMedGoogle Scholar
  • 5 El Tahir KE H, Betteridge DJ, Reckless JP, Williams KI. Stability of prostacyclin in human plasma. Clin Sci 1980; 59: 28-29
    PubMedGoogle Scholar
  • 6 Borda ES, Lazzari MA, Gimeno MF, Gimeno AL. Human platelet rich plasma and human serum protects from inactivation the antiaggregatory capacity of prostacyclin-like material (PGI2) produced by the rat stomach fundus. Prostaglandins 1980; 19: 899-905
    CrossrefPubMedGoogle Scholar
  • 7 MacIntyre D, Steer M, Galgoci B, Khorana J, Levine L, Salzman E. Removal or decay of PI reverses its effect on platelet cAMP levels and platelet aggregation. Abstracts of the Fourth Int Prostaglandin Conf 1979; Abstract 73 a
    PubMedGoogle Scholar
  • 8 O’Grady J, Warrington S, Moti MJ, Bunting S, Flower R, Fowle AS, Higgs EA, Moncada S. Effects of intravenous infusion of prostacyclin in man. Prostaglandins 1980; 19: 319-332
    CrossrefPubMedGoogle Scholar
  • 9 Smith JB, Ingerman C, Silver MJ. Persistence of thromboxane A2- like material and platelet release-inducing activity in plasma. J Clin Invest 1976; 58: 1119-1122
    CrossrefPubMedGoogle Scholar
  • 10 Lagarde M, Velardo B, Blanc M, Dechavanne M. Fatty acids bound to albumin decrease the half-life of thromboxane A2 . Prostaglandins 1980; 20: 275-283
    CrossrefPubMedGoogle Scholar
  • 11 Folco G, Grandstrom E, Kindahl H. Albumin stabilises thromboxane A2 . FEBS Letters 1977; 82: 321-324
    CrossrefPubMedGoogle Scholar
  • 12 Orchard MA, Robinson C. Prostacyclin is stabilised by serum albumin. Br J Pharmacol 1981; 74: 206
    PubMedGoogle Scholar
  • 13 Dusting GJ, Moncada S, Vane JR. Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmacol 1978; 64: 315-320
    CrossrefPubMedGoogle Scholar
  • 14 Wynalda MA, Fitzpatrick FA. Albumins stabilise prostaglandin I2 . Prostaglandins 1980; 20: 853-861
    CrossrefPubMedGoogle Scholar
  • 15 Pifer DD, Cagen LM. Chesney C Mcl. Stability of prostaglandin I2 in human blood. Prostaglandins 1981; 21: 165-175
    PubMedGoogle Scholar
  • 16 Rao GH, Reddy KR, Hagert K, White JG. Influence of pH on the prostacyclin (PGI2) mediated inhibition of platelet function. Prostaglandins Med 1980; 4: 263-273
    CrossrefPubMedGoogle Scholar
  • 17 Birkett DJ, Myers SP, Sudlow G. The fatty acid content and drug binding characteristics of commercial albumin preparations. Clin Chim Act 1978; 85: 253-258
    CrossrefPubMedGoogle Scholar
  • 18 Gueriguian JL. Noncovalent binding of prostaglandins A1, E1 F2α and E2 by human and bovine serum albumins. J Pharmacol Exper Ther 1976; 197: 319-401
    PubMedGoogle Scholar
  • 19 Spector AA. Fatty acid binding to plasma albumin. J Lipid Res 1975; 16: 165-176
    PubMedGoogle Scholar
  • 20 Chiang Y, Kresge AJ, Cho MJ. Acid-catalysed hydrolysis of prostacyclin: origin of the unused lability. J C S Chem Comm 1979; 129-130
    PubMedGoogle Scholar
  • 21 McClenaghan MD, Haslam RJ. A sensitive assay for prostacyclin (PGI2) applicable to fresh rabbit blood. Fed Proc 1980; 39: 323
    PubMedGoogle Scholar
  • 22 Willems Ch, van Aken WG, van Mourik JA. Binding of prostacyclin (PGI2) to human erythrocytes. Acta Therapeutica 1980; 6 (suppl) 31
    PubMedGoogle Scholar
  • 23 Baroody RA, Bito LZ. The impermeability of the basic cell membrane to thromboxane B2, prostacyclin and 6-keto-PGF1α . Prostaglandins 1981; 21: 133-142
    CrossrefPubMedGoogle Scholar